<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01838265</url>
  </required_header>
  <id_info>
    <org_study_id>UMIAMI-20120698</org_study_id>
    <nct_id>NCT01838265</nct_id>
  </id_info>
  <brief_title>Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management</brief_title>
  <acronym>MGM</acronym>
  <official_title>A Randomized Two-Arm Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management: The MGM Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami Sylvester Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami Sylvester Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Using multiparametric MRI Ultrasound-guided or MRI-guided biopsies will allow more
           accurate sampling of the tumors and therefore will increase the rate of &quot;progression&quot;
           on early (first and second) surveillance biopsies and decrease the rate of
           &quot;progression&quot; on late (third and further) surveillance biopsies compared to Transrectal
           Ultrasound-guided biopsies.

        2. Quality of life (QoL) will be similar in patients undergoing MRI Ultrasound or
           MRI-guided and Transrectal Ultrasound-guided biopsies.

        3. Biomarker expression levels will correlate with biopsy progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Favorable risk patients will be randomized to one of two active surveillance arms.
      Stratification will be based on Prostate-specific antigen density (PSAD) (=&lt; 0.15 vs &gt; 0.15
      ng/mL per mL), and number of positive cores in the diagnostic biopsy (1 vs 2):

        -  Arm I: Active Surveillance Alone (AS). TRUS guided biopsies at start (within 6 months
           of enrollment) and at yearly intervals thereafter up to 36 months after the initial
           biopsy (maximum four biopsies).

        -  Arm II: MRI-Managed Active Surveillance (MRI-AS). MRIus or MRI-guided biopsies at start
           (within 6 months of enrollment) and at yearly intervals thereafter up to 36 months
           after the initial biopsy (maximum four biopsies).

      Patients will also complete Quality of Life (QoL) assessments to provide unique data on the
      effects of MRI monitoring for patients undergoing active surveillance on QOL. The
      investigators have selected a group of measures that have been used extensively in prostate
      cancer populations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of Progression in Subjects undergoing MRIus Biopsy vs Standard Ultrasound biopsy</measure>
    <time_frame>42 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine of multiparametric MRIus-guided biopsies increase the rate of progression on early (first two) biopsies in men undergoing active surveillance as compared with early detection using standard ultrasound biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression Levels of Biomarkers from biopsies collected with MRI-us Biopsy vs Standard Ultrasound Biopsy</measure>
    <time_frame>42 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of MRI Monitoring on Health-Related Quality of Life</measure>
    <time_frame>42 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effect of MRI monitoring on health-related quality of life (HRQOL), prostate cancer-specific anxiety QOL (ie general, PSA-testing &amp; recurrence anxiety, PC-Anxiety) and prostate cancer-specific QOL (ie sexual, urinary &amp; bowel function, PC-QOL), particularly as they relate to ethnically and socioeconomically diverse and disparate populations.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <description>Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
    <description>MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal Ultrasound-Guided Biopsy</intervention_name>
    <description>Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <other_name>TRUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Ultrasound Biopsy</intervention_name>
    <description>MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)</description>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Expanded Prostate Cancer index Composite Questionnaire</intervention_name>
    <description>Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
    <other_name>EPIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Short-Form 12 of Health Related Quality of Life Questionnaire</intervention_name>
    <description>Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
    <other_name>SF-12</other_name>
    <other_name>SF-12 HRQOL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Memorial Anxiety Scale for Prostate Cancer</intervention_name>
    <description>Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
    <other_name>MAX-PC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma/Serum Sample for biomarkers</intervention_name>
    <description>Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine Sample for Biomarkers</intervention_name>
    <description>Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Tests for Blood Urea Nitrogen and Creatinine</intervention_name>
    <description>Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Test for Serum PSA</intervention_name>
    <description>Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.</description>
    <arm_group_label>AS: Active Surveillance Alone</arm_group_label>
    <arm_group_label>MRI-AS: MRI+ Active Surveillance</arm_group_label>
    <other_name>PSA test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy tumor tissue, blood and urine samples for correlative studies (circulating tumor
      cells (CTC), free-circulating DNA (fcDNA) and single nucleotide polymorphisms (SNPs)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Low risk male patients with early stage T1 - T2a prostate adenocarcinoma, based on  a
        digital rectal exam palpation. Patients must also have less than three positive cores with
        &lt; 50% of a single core; and Gleason score 3 + 3 = 6 or less.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy confirmed adenocarcinoma of the prostate.

          -  Biopsy must consist of at least 8 cores.

          -  Enrollment is =&lt; 1 year from diagnosis.

          -  One or two biopsy cores with less than 50% tumor present in each core and Gleason
             score =&lt; 6 (3+3).

          -  Candidate for multiparametric MRI.

          -  T1-T2a disease based on digital rectal exam.

          -  No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage
             chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma).
             If a prior malignancy is in remission for &gt;= 5 years then the patient is eligible.

          -  Ability to understand and willingness to sign a written informed consent document

          -  Zubrod performance status &lt; 2.

          -  Patients must agree to fill out the psychosocial questionnaires.

          -  Age &gt;= 35 and =&lt; 75 years

        Exclusion Criteria:

          -  Not biopsy confirmed adenocarcinoma of the prostate.

          -  Biopsy consists of less than 8 cores.

          -  Three or more biopsy cores are positive.

          -  Gleason score &gt;= 3+4=7.

          -  A single core has &gt;= 50% involvement with Gleason score =6 (3+3) or less.

          -  DCE-MRI study before enrollment.

          -  Inability to undergo MRI exam.

          -  Greater than T2a disease based on digital rectal exam.

          -  Concurrent, active malignancy, other than nonmetastatic skin cancer or early stage
             chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma).
             If a prior malignancy is in remission for &lt; 5 years then the patient is ineligible

          -  Inability to understand or unwilling to sign a written informed consent document.

          -  Zubrod performance status &gt;= 2.

          -  Patient unwilling to fill out the psychosocial questionnaires.

          -  Age &lt; 35 or &gt; 75.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Soloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Institutional Review Board</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Pollack, MD</last_name>
      <phone>305-243-4916</phone>
      <email>apollack@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>University of Miami Sylvester Comprehensive Cancer Center</last_name>
      <phone>866-574--5124</phone>
      <email>sylvester@emergingmed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Soloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Abramowitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Javier Casillas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Cote, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ram Datar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merce Jorda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Hu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Kava, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Leveillee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vinata Lokeshwar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Lynne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murugesan Manoharan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rakesh Singal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radka Stoyanova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saleem Umar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
